A groundbreaking clinical trial conducted at a leading Shanghai hospital has demonstrated remarkable results in the treatment of relapsed B-cell lymphoma using a new generation CAR-T cell therapy.
Key Findings
The Phase II clinical trial, involving 120 patients with relapsed or refractory B-cell lymphoma, showed a 90% complete remission rate within three months of CAR-T cell infusion. This represents a significant improvement over previous generations of CAR-T therapy.
What Makes This Different
The new generation CAR-T therapy developed by the Shanghai research team incorporates several innovations:
- Dual-targeting approach that recognizes two different antigens on cancer cells
- Enhanced persistence of CAR-T cells in the body
- Reduced cytokine release syndrome (CRS) side effects
- Faster manufacturing process (reduced from 14 days to 7 days)
Implications for International Patients
This breakthrough further solidifies China's position as a global leader in CAR-T cell therapy. International patients can access this cutting-edge treatment at a fraction of the cost compared to similar treatments in the United States or Europe.
The total cost of CAR-T therapy in Shanghai, including hospitalization and monitoring, is typically 200,000-400,000 RMB (approximately $28,000-$56,000 USD), compared to $400,000-$500,000 in the United States.
Next Steps
The research team is now preparing for a Phase III multi-center trial and has applied for expanded access programs that would allow international patients to participate.